IL13 and psoriasis: In particular, Trajectory 1, utilized predominantly by AD and psoriasis, displayed significant overall upregulation of IFNγ (AD log2FC 0.286, FDR adjusted p = 2.7e‐06; psoriasis log2FC 0.248, FDR adjusted p = 2.7e‐06) and IL‐4 + IL‐13 signatures (AD log2FC 0.288, FDR adjusted p = 4.0e‐04; psoriasis log2FC 0.281, FDR adjusted p = 2.5e‐04), alongside TGFβ (AD log2FC 0.23, FDR adjusted p = 3.7e‐05; psoriasis log2FC 0.152, FDR adjusted p = 2.1e‐03) compared to healthy subjects, suggesting mixed T1–T2 and anti‐inflammatory responses in the dermis of affected patients (Figure S11).